arrow
L

Lindsay N. Carpp

Fred Hutch Cancer Center
H指数:30
被引数:5,150

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants

先前感染SARS-CoV-2与未感染的COVAIL试验参与者在二次加强针前后COVID-19风险的T细胞相关性差异

2026-10-060
OAAI
mRNA-1273 SARS-CoV-2 vaccination in people with HIV: an immune correlates analysis of CD4 + T cell responses in the multicenter CoVPN 3008 observational study

mRNA-1273 SARS-CoV-2疫苗接种在HIV感染者中的免疫相关分析:多中心CoVPN 3008观察性研究中CD4+ T细胞反应

2026-09-280
OAAI
Quantifying how HIV-1 envelope sequence features impact vaccine efficacy in the HVTN 705/HPX2008 randomised trial in southern African women

量化HIV-1包膜序列特征如何影响HVTN 705/HPX2008随机试验中南部非洲女性的疫苗效果

2026-08-010
PRE
Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections

VRC01 HIV-1预防性治疗的体内持续活性涉及初始保护效果及后续突破性感染

2026-01-010
OA
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV

中和抗体和结合抗体是CoVPN 3008研究中HIV感染者COVID-19风险的相关因素。

2025-10-060
OAAI
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine

NVX-CoV2373重组蛋白疫苗PREVENT-19疗效试验中抗体标志物作为严重COVID-19风险免疫相关指标的分析

2025-10-010
PRE
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial

SARS-CoV-2变异株抗体反应的免疫相关性分析:ENSEMBLE疫苗有效性试验

2025-09-290
OAAI
Bayesian estimation of HIV acquisition dates for prevention trials

贝叶斯方法估计HIV感染日期用于预防试验

MBIO
IF4.7
2025-09-010
OA
Corrigendum to ‘Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study’. EBioMedicine 2024;108: 105320

勘误:‘在南部非洲出生时被指定为女性的人群中评估的镶嵌HIV-1疫苗方案免疫原性试验的免疫相关性分析:一项两阶段病例对照研究’。EBioMedicine 2024;108: 105320

2025-08-230
PREAI
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+T cell responses among 13 HIV vaccine trials

一种多价的DNA初始免疫与匹配的多价蛋白/GLA-SE加强方案的组合,在13项HIV疫苗试验中诱发了最强大且广泛的IgG和IgG3 V1V2结合抗体以及CD4+T细胞反应。

2025-04-070
OAAI
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people female sex at birth: a case-control study
2024-10-010
PRE
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

COVE试验中第三剂mRNA-1273的Omicron新型冠状病毒肺炎免疫相关分析

2024-09-110
OAAI
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials ( vol 14 , 8299 , 2023)
2024-03-220
OAAI
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
2024-03-112
OAAI
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features

广泛中和抗体VRC01的预防功效取决于HIV-1的包膜序列特征

2024-01-194
OAAI
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
2023-12-144
OAAI
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
2023-09-297
OAAI
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
2023-04-1913
OAAI
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial (vol 14, 331, 2023)
2023-03-222
OAAI